Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) (Q56978661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

diffuse large B-cell lymphoma

1 reference

1 reference

René-Olivier Casasnovas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Corinne Haioun

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

N Ketterer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

B Coiffier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Thieblemont

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Fermé

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

J Brière

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

S Bologna

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

B Christian

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

T Connerotte

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Récher

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

D Bordessoule

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Fruchart

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

R Delarue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Bonnet

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

F Morschhauser

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

B Anglaret

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Soussain

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

B Fabiani

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

H Tilly

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

12 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1032-1037

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS600

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS600

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235801%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference